3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Lady wearing a head scarf looks over pages on company financials
Investing Articles

Is April a good time to start buying shares?

Wondering whether now's a good time to start buying shares to build wealth? History suggests it is, says Edward Sheldon.

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How much passive income could a Stocks and Shares ISA pump out every year?

Regular investing inside a Stocks and Shares ISA could lead to the equivalent of £141 a week in tax-free passive…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With the FTSE 100 down 5%+ investors should remember this legendary quote from Warren Buffett

Warren Buffett is widely regarded as the greatest investor of all time. And he says that the best time to…

Read more »

Inflation in newspapers
Investing Articles

1 FTSE 100 stock that could benefit from higher inflation

For most companies, inflation is a risk. But for one FTSE 100 firm, higher input costs could be an opportunity…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

The 2026 stock market sell-off could be a rare opportunity to build wealth in an ISA

The recent stock market sell-off has led to some shares falling 20% or more. This could be a great opportunity…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

It’s down another 13%! Analysts were dead wrong about the Greggs share price

The Greggs share price continues to fall and analysts have been revising their share price targets down further. Dr James…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Is the stock market about to reach breaking point?

Private credit has a problem with the emergence of artificial intelligence. And it could be set to create issues across…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

A once-in-a-decade chance to buy this S&P 500 stock?

As investors focus on oil prices and the conflict in Iran, Stephen Wright's looking at potential opportunities in the S&P…

Read more »